August 15, 2025 · Form 4 insider transaction
Fitzgerald Kevin Joseph bought 2,851 shares of Alnylam Pharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.